文献速递流行病学与生物统计真实世界研究与卫生经济

2019年全球早产儿和低龄儿童呼吸道合胞病毒所致急性下呼吸道感染的疾病负担及危险因素:聚合数据与个体参与者数据的系统评价和Meta分析

Global disease burden of and risk factors for acute lower respiratory infections caused by respiratory syncytial virus in preterm infants and young children in 2019: a systematic review and meta-analysis of aggregated and individual participant data.
PubMed 文献 · Lancet · 2024-02-14

该研究通过系统评价和Meta分析(聚合数据1995年1月1日至2021年12月31日,47项文献研究及17项个体参与者数据研究),评估2019年全球早产儿RSV相关急性下呼吸道感染的疾病负担及危险因素。早产儿占所有婴儿RSV相关ALRI住院的25%。早期早产儿住院负担持续至生后第二年,严重结局主要与基础疾病相关。

要点

  • 早产儿占所有婴儿RSV相关ALRI住院的25%(95%UR 16-37)。
  • 早期早产儿RSV住院负担持续至生后第二年,RR 2.26(95%UR 1.27-3.98)。

核心结论

  • 早产儿面临不成比例的RSV相关疾病负担,占RSV住院负担的25%。
  • 早期早产儿的显著RSV住院负担持续至生后第二年。
  • RSV预防产品可通过预防早产儿RSV相关ALRI及感染严重结局产生重大公共卫生影响。

研究设计与样本

  • 系统评价和Meta分析,纳入1995年1月1日至2021年12月31日发表的聚合数据研究及呼吸道病毒全球流行病学网络共享的个体参与者数据。
  • 共纳入47项文献研究和17项个体参与者数据研究。
  • 采用两阶段随机效应Meta回归分析,考虑实足年龄组、胎龄带(早期早产<32周胎龄和晚期早产32至<37周胎龄)及2000至2019年每5年间隔变化。
  • 使用个体参与者数据通过两阶段Meta分析(多变量logistic回归和随机效应Meta分析)评估围产期、社会人口学、家庭因素及基础疾病与RSV相关ALRI发生率、住院及三个严重结局组的合并OR。
  • 研究注册于PROSPERO,CRD42021269742。

主要发现

  • 2019年全球早产儿中估计发生1 650 000例(95%UR 1 350 000-1 990 000)RSV相关ALRI发作。
  • 2019年全球早产儿中估计发生533 000例(95%UR 385 000-730 000)RSV相关住院。
  • 2019年全球早产儿中估计发生3050例(95%UR 1080-8620)RSV相关院内死亡和26 760例(95%UR 11 190-46 240)RSV归因死亡。
  • 早期早产儿RSV相关ALRI发病率和住院率显著高于任何胎龄的所有婴儿,不同年龄组和结局的率比(RR)范围为1.69至3.87。
  • 生后第二年,早期早产儿发病率与所有婴幼儿相似,但住院率仍显著更高(RR 2.26 [95%UR 1.27-3.98])。

关键数值与推荐

  • 早期早产儿RSV相关ALRI发病率和住院率显著高于所有胎龄婴儿,RR范围为1.69至3.87。
  • 生后第二年早期早产儿住院率RR 2.26(95%UR 1.27-3.98)。
  • 晚期早产儿生后前6个月住院率RR 1.93(95%UR 1.11-3.26)。
  • 早产儿占所有婴儿RSV相关ALRI住院的25%(95%UR 16-37)。
  • 基础疾病与严重结局的OR范围为1.40至4.23。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Infants and young children born prematurely are at high risk of severe acute lower respiratory infection (ALRI) caused by respiratory syncytial virus (RSV). In this study, we aimed to assess the global disease burden of and risk factors for RSV-associated ALRI in infants and young children born before 37 weeks of gestation. METHODS: We conducted a systematic review and meta-analysis of aggregated data from studies published between Jan 1, 1995, and Dec 31, 2021, identified from MEDLINE, Embase, and Global Health, and individual participant data shared by the Respiratory Virus Global Epidemiology Network on respiratory infectious diseases. We estimated RSV-associated ALRI incidence in community, hospital admission, in-hospital mortality, and overall mortality among children younger than 2 years born prematurely. We conducted two-stage random-effects meta-regression analyses accounting for chronological age groups, gestational age bands (early preterm, <32 weeks gestational age [wGA], and late preterm, 32 to <37 wGA), and changes over 5-year intervals from 2000 to 2019. Using individual participant data, we assessed perinatal, sociodemographic, and household factors, and underlying medical conditions for RSV-associated ALRI incidence, hospital admission, and three severity outcome groups (longer hospital stay [>4 days], use of supplemental oxygen and mechanical ventilation, or intensive care unit admission) by estimating pooled odds ratios (ORs) through a two-stage meta-analysis (multivariate logistic regression and random-effects meta-analysis). This study is registered with PROSPERO, CRD42021269742. FINDINGS: We included 47 studies from the literature and 17 studies with individual participant-level data contributed by the participating investigators. We estimated that, in 2019, 1 650 000 (95% uncertainty range [UR] 1 350 000-1 990 000) RSV-associated ALRI episodes, 533 000 (385 000-730 000) RSV-associated hospital admissions, 3050 (1080-8620) RSV-associated in-hospital deaths, and 26 760 (11 190-46 240) RSV-attributable deaths occurred in preterm infants worldwide. Among early preterm infants, the RSV-associated ALRI incidence rate and hospitalisation rate were significantly higher (rate ratio [RR] ranging from 1·69 to 3·87 across different age groups and outcomes) than for all infants born at any gestational age. In the second year of life, early preterm infants and young children had a similar incidence rate but still a significantly higher hospitalisation rate (RR 2·26 [95% UR 1·27-3·98]) compared with all infants and young children. Although late preterm infants had RSV-associated ALRI incidence rates similar to that of all infants younger than 1 year, they had higher RSV-associated ALRI hospitalisation rate in the first 6 months (RR 1·93 [1·11-3·26]). Overall, preterm infants accounted for 25% (95% UR 16-37) of RSV-associated ALRI hospitalisations in all infants of any gestational age. RSV-associated ALRI in-hospital case fatality ratio in preterm infants was similar to all infants. The factors identified to be associated with RSV-associated ALRI incidence were mainly perinatal and sociodemographic characteristics, and factors associated with severe outcomes from infection were mainly underlying medical conditions including congenital heart disease, tracheostomy, bronchopulmonary dysplasia, chronic lung disease, or Down syndrome (with ORs ranging from 1·40 to 4·23). INTERPRETATION: Preterm infants face a disproportionately high burden of RSV-associated disease, accounting for 25% of RSV hospitalisation burden. Early preterm infants have a substantial RSV hospitalisation burden persisting into the second year of life. Preventive products for RSV can have a substantial public health impact by preventing RSV-associated ALRI and severe outcomes from infection in preterm infants. FUNDING: EU Innovative Medicines Initiative Respiratory Syncytial Virus Consortium in Europe.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Wang X, Li Y, Shi T, et al. Global disease burden of and risk factors for acute lower respiratory infections caused by respiratory syncytial virus in preterm infants and young children in 2019: a systematic review and meta-analysis of aggregated and individual participant data. Lancet. 2024. PMID: 38367641. doi:10.1016/S0140-6736(24)00138-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。